66 related articles for article (PubMed ID: 25429835)
1. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
Amelot A; De Cremoux P; Quillien V; Polivka M; Adle-Biassette H; Lehmann-Che J; Françoise L; Carpentier AF; George B; Mandonnet E; Froelich S
PLoS One; 2015; 10(7):e0130596. PubMed ID: 26158269
[TBL] [Abstract][Full Text] [Related]
2. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.
Liu Q; Liu Y; Li W; Wang X; Sawaya R; Lang FF; Yung WK; Chen K; Fuller GN; Zhang W
Acta Neuropathol; 2015 Oct; 130(4):587-97. PubMed ID: 26323991
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.
Kim BYS; Jiang W; Beiko J; Prabhu SS; DeMonte F; Gilbert MR; Sawaya R; Aldape KD; Cahill DP; McCutcheon IE
J Neurooncol; 2014 Jun; 118(2):405-412. PubMed ID: 24777756
[TBL] [Abstract][Full Text] [Related]
4. Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma.
Swellam M; Khalifa MK; Nageeb AM; Ezz El-Arab L; El-Mahdy M; El-Bahy K; Sayed Mahmoud M
Int J Immunopathol Pharmacol; 2024; 38():3946320241250294. PubMed ID: 38686946
[TBL] [Abstract][Full Text] [Related]
5. COVPRIG robustly predicts the overall survival of IDH wild-type glioblastoma and highlights METTL1
Ji H; Wang F; Liu Z; Li Y; Sun H; Xiao A; Zhang H; You C; Hu S; Liu Y
J Transl Med; 2023 Aug; 21(1):533. PubMed ID: 37553713
[TBL] [Abstract][Full Text] [Related]
6. Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance.
Cai J; Zhang W; Yang P; Wang Y; Li M; Zhang C; Wang Z; Hu H; Liu Y; Li Q; Wen J; Sun B; Wang X; Jiang T; Jiang C
PLoS One; 2015; 10(5):e0126022. PubMed ID: 25978454
[TBL] [Abstract][Full Text] [Related]
7. D-Loop Mutations as Prognostic Markers in Glioblastoma-A Pilot Study.
Szmyd B; Stanisławska P; Podstawka M; Zaczkowski K; Izbiński PM; Kulczycka-Wojdala D; Stawski R; Wiśniewski K; Janczar K; Braun M; Białasiewicz P; Jaskólski DJ; Bobeff EJ
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673919
[TBL] [Abstract][Full Text] [Related]
8. High Matrix Metalloproteinase 28 Expression is Associated with Poor Prognosis in Pancreatic Adenocarcinoma.
Liu N; Zhong L; Ni G; Lin J; Xie L; Li T; Dan H; Chen Q
Onco Targets Ther; 2021; 14():4391-4406. PubMed ID: 34408436
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
[TBL] [Abstract][Full Text] [Related]
10. Expression and Clinical Significance of MMP-28 in Bladder Cancer.
Wang H; Wu JX; Chen XP; Zhang Q; Wei HB; Wang HJ; Yang X; Zhang DH
Technol Cancer Res Treat; 2020; 19():1533033820974017. PubMed ID: 33191847
[TBL] [Abstract][Full Text] [Related]
11. Correlation Between Plasma Matrix Metalloproteinase-28 Levels and Severity of Calcific Aortic Valve Stenosis.
Zhou K; Guo T; Xu Y; Guo R
Med Sci Monit; 2020 Sep; 26():e925260. PubMed ID: 32950995
[TBL] [Abstract][Full Text] [Related]
12. Circulating Matrix Metalloproteinase-28 Levels Are Related to GRACE Scores and Short-Term Outcomes in Patients with Acute Myocardial Infarction.
Zhou K; Li Y; Xu Y; Guo R
Biomed Res Int; 2020; 2020():9206703. PubMed ID: 32596395
[TBL] [Abstract][Full Text] [Related]
13. High MMP-26 expression in glioma is correlated with poor clinical outcome of patients.
Guo JG; Guo CC; He ZQ; Cai XY; Mou YG
Oncol Lett; 2018 Aug; 16(2):2237-2242. PubMed ID: 30008924
[TBL] [Abstract][Full Text] [Related]
14. Epilysin is overexpressed in glioblastoma and related to clinical outcome of patients.
Wang X; Zhang K; Chen X; Zhao C; Sun Z
Med Oncol; 2015 Jan; 32(1):363. PubMed ID: 25429835
[TBL] [Abstract][Full Text] [Related]
15. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
16. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
17. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
Zhao H; Wang S; Song C; Zha Y; Li L
World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
